意大利和西班牙社区获得性呼吸道感染病原菌耐药监测(SOAR 2018-21)
该研究采用CLSI微量肉汤稀释法测定2018-21年意大利和西班牙社区获得性呼吸道感染分离的肺炎链球菌和流感嗜血杆菌的MIC,并用CLSI、EUCAST及PK/PD折点解读药敏。结果显示肺炎链球菌对多数抗生素敏感率低,仅高剂量青霉素和氟喹诺酮类敏感率>90%;流感嗜血杆菌敏感率较高。
要点
- 肺炎链球菌对多数抗生素敏感率低,仅高剂量青霉素和氟喹诺酮类敏感率>90%。
- 流感嗜血杆菌对多数抗生素敏感率>90%,但氨苄西林和复方磺胺甲噁唑敏感率较低。
- 持续耐药监测对指导社区获得性呼吸道感染经验治疗重要。
核心结论
- 两国肺炎链球菌对许多抗生素敏感率低,仅高剂量青霉素、氟喹诺酮类及高剂量阿莫西林/克拉维酸(PK/PD)敏感率>90%。
- 流感嗜血杆菌敏感率较高,但氨苄西林和复方磺胺甲噁唑敏感率较低。
研究设计与样本
- 2018-21年从意大利和西班牙社区获得性呼吸道感染患者中收集肺炎链球菌和流感嗜血杆菌临床分离株。
- 意大利收集77株肺炎链球菌和249株流感嗜血杆菌,西班牙收集176株肺炎链球菌和275株流感嗜血杆菌。
- 采用CLSI微量肉汤稀释法测定MIC,并用CLSI、EUCAST及PK/PD折点解读药敏。
主要发现
- 按CLSI口服或EUCAST低剂量折点,约65%肺炎链球菌对青霉素敏感;按EUCAST高剂量或CLSI静脉给药折点,意大利和西班牙敏感率分别为92.2%和95.5%。
- 意大利肺炎链球菌对阿莫西林/克拉维酸、阿莫西林和多数头孢菌素敏感率(CLSI)为71.4%-89.6%。
- 意大利肺炎链球菌对头孢克洛、四环素类、大环内酯类和复方磺胺甲噁唑敏感率(51.9%-67.5%)低于西班牙(67.0%-81.2%)。
- 氟喹诺酮类对肺炎链球菌活性最强(≥99.4%,EUCAST低剂量除外)。
- 流感嗜血杆菌产β-内酰胺酶率意大利14.1%、西班牙17.1%;氨苄西林耐药(CLSI)意大利0.5%、西班牙3.1%。
关键数值与推荐
- 肺炎链球菌对青霉素敏感率:CLSI口服或EUCAST低剂量折点约65%;EUCAST高剂量或CLSI静脉折点意大利92.2%、西班牙95.5%。
- 意大利肺炎链球菌对阿莫西林/克拉维酸、阿莫西林和多数头孢菌素敏感率(CLSI)71.4%-89.6%。
- 意大利肺炎链球菌对头孢克洛、四环素类、大环内酯类和复方磺胺甲噁唑敏感率51.9%-67.5%,西班牙67.0%-81.2%。
- 氟喹诺酮类对肺炎链球菌敏感率≥99.4%(EUCAST低剂量除外)。
- 流感嗜血杆菌敏感率(CLSI)>90%,但氨苄西林(意大利82.7%、西班牙81.1%)和复方磺胺甲噁唑(意大利71.1%、西班牙68.0%)较低;EUCAST头孢呋辛敏感率意大利82.3%、西班牙87.3%(增加暴露),CLSI为100%。
临床怎么用
- 社区获得性呼吸道感染经验治疗应参考当地耐药监测数据。
- 肺炎链球菌感染可优先考虑高剂量青霉素、氟喹诺酮类或高剂量阿莫西林/克拉维酸。
- 流感嗜血杆菌对多数抗生素敏感率高,但氨苄西林和复方磺胺甲噁唑敏感性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the antibiotic susceptibility of community-acquired respiratory tract infection (CA-RTI) Streptococcus pneumoniae and Haemophilus influenzae isolates from Italy and Spain, 2018-21. METHODS: MICs were determined by CLSI broth microdilution, and susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 77 S. pneumoniae and 249 H. influenzae were collected from Italy and 176 S. pneumoniae and 275 H. influenzae from Spain. Approximately 65% of pneumococci were penicillin-susceptible by CLSI oral or EUCAST low-dose breakpoints; by EUCAST high-dose or CLSI intravenous administration, 92.2%/95.5% (Italy/Spain) were susceptible. In Italy, 71.4% to 89.6% susceptibility (CLSI) was observed to amoxicillin/clavulanic acid, amoxicillin and most cephalosporins. Cefaclor, tetracyclines, macrolides and trimethoprim/sulfamethoxazole were less active against Italian (51.9%-67.5% susceptible) versus Spanish (67.0%-81.2% susceptible) isolates. The most potent antibiotics were fluoroquinolones (≥99.4%, excluding EUCAST low-dose). Most H. influenzae isolates were β-lactamase negative with a few ampicillin-resistant isolates (CLSI: 0.5% Italy, 3.1% Spain). Rates of β-lactamase positivity were 14.1% (Italy) and 17.1% (Spain). Susceptibility was >90% (CLSI) except for ampicillin (82.7% Italy, 81.1% Spain) and trimethoprim/sulfamethoxazole (71.1% Italy, 68.0% Spain). Susceptibility by EUCAST was similar to CLSI, except for cefuroxime (82.3% Italy, 87.3% Spain susceptible, increased exposure versus 100% by CLSI). CONCLUSIONS: Susceptibility of S. pneumoniae to many antibiotics was low in both countries, with susceptibility > 90% observed only with high-dose penicillin and fluoroquinolones (CLSI and EUCAST) and high-dose amoxicillin or amoxicillin/clavulanic acid (PK/PD). Higher susceptibility was seen with H. influenzae in both countries. Continued surveillance of antimicrobial resistance is important for guiding therapy of CA-RTIs.
引用
- Torumkuney D, Canton R, Pitart C, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Italy and Spain: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2025. PMID: 41277337. doi:10.1093/jac/dkaf283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。